Nuformix PLC - Annual Report and Notice of AGM

16th August 2018, 06:00

RNS Number : 9532X
Nuformix PLC
16 August 2018

16 August 2018


Nuformix Plc

("Nuformix" or the "Company")


2018 Annual Financial Report and Notice of Annual General Meeting


The Company announces that the following documents were posted to its shareholders:


·     Annual Financial Report 2018

·     2018 Notice of Annual General Meeting and Proxy Form


A full pdf version of the Annual Financial Report 2018 together with the Notice of Annual General Meeting and sample Proxy Form are available for download from the Document Center section on the Company's website


Copies of the Annual Financial Report 2018 and the Notice of 2018 Annual General Meeting and Proxy Form have been submitted to the National Storage Mechanism and will be available for inspection in due course at  The Nuformix Annual Financial Report will be filed with the Registrar of Companies in due course and copies can be obtained from the Company Secretary, SGH Company Secretaries Limited, 60 Gracechurch Street, London, EC3V 0HR.


The Annual General Meeting will be held on Wednesday 19 September 2018 at 1.00 pm at the offices of Shakespeare Martineau, 6th floor, 60 Gracechurch Street, London, EC3V 0HR.



For further information please contact:


Nuformix plc    

Dan Gooding, Chief Executive Officer

+44 (0)1223 423 667


SGH Company Secretaries Ltd

Ben Harber

+44 (0)207 264 4366


Gable Communications Ltd 

John Bick or Justine James

+44 (0)20 7193 7463



About Nuformix plc: 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs.   Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.  Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Companies mentioned in this announcement


Login or register to post comments